PsiOxus Appoints GSK's Former Oncology President As Chair
This article was originally published in Scrip
PsiOxus Therapeutics Ltd. has appointed Paolo Paoletti chair of its board of directors. Most recently, Paoletti was president of GlaxoSmithKline (GSK) Oncology and prior to this he was vice president of clinical development for Lilly Oncology. Currently, Paoletti is CEO of Kesios Therapeutics and is on the board for Genmab A/S, FORMA Therapeutics and Nucana BioMed.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.